FOSUN HEALTH Logo

Colorectal Cancer Treatment

catalogue

Colorectal Cancer Treatment

Colorectal Cancer Treatment

Two questions shape colorectal cancer treatment more than any other: whether the operation can preserve the sphincter, and whether the disease outside the bowel can be cleared completely. Both are answered by imaging and molecular testing, not by assumption.

Treatment by stage: sequence before inventory

What separates one colorectal plan from another is usually the order of treatments rather than which treatments exist. The table below sets out the usual sequence; each row carries exceptions decided by the MRI findings and the molecular profile.

Stage Usual sequence What decides the details
0 · carcinoma in situ Endoscopic removal where the lesion can be cleared completely, otherwise segmental surgery Depth of invasion, completeness of endoscopic removal, and whether the lesion is in the colon or the rectum
I Surgery alone Depth of invasion; whether the tumour is at high risk of recurrence
II Surgery, with chemotherapy considered only where risk features are present MSI status, the number of nodes examined, perineural or lymphovascular invasion, obstruction or perforation at presentation
III Surgery followed by chemotherapy; for rectal cancer, treatment before surgery in most cases Nodal involvement and MRI findings for rectal tumours; the molecular profile for the choice of regimen
IV · limited liver deposits Systemic therapy with planned local treatment of the liver — resection, ablation or arterial therapy Number, size and distribution of deposits; whether disease outside the liver can also be cleared
IV · widespread disease Systemic therapy in successive lines, guided by re-testing at progression The molecular profile at progression, symptoms, and which organs are involved
In stage IV disease, the question is not "how many organs" but "can all of it be removed". Where liver deposits are limited to one lobe and there is no disease elsewhere that cannot be dealt with, an operation intended to remove all visible disease is a realistic aim, and it is planned before systemic treatment rather than after it fails. Where the distribution does not allow that, the goal shifts to sustained control — which is a different aim, not a lesser one.

Surgery: complete excision with nerve preservation

The operation has two simultaneous objectives: removing the tumour with an adequate margin and its lymph node basin, and preserving the nerves that control bowel, urinary and sexual function.

The precision the pelvis requires

"The tumour is low. Will I lose control of my bowel, or need a permanent stoma?"

For rectal cancer, total mesorectal excision removes the rectum together with the fatty envelope containing its lymph nodes, dissecting along an anatomically defined plane. Our surgeons perform this with the robotic platform, whose 10× magnified three-dimensional vision and tremor-free wristed instruments allow that plane to be followed accurately inside a narrow pelvis while the autonomic nerves are identified and preserved. For colon cancer, complete mesocolic excision applies the same principle — dissecting along the embryological plane and taking the central lymph nodes with the vessel. Both reduce the risk of a positive margin and of the functional consequences that follow nerve injury.

Margin adequateAutonomic nerves preservedNodal basin removedFunction prioritised

Where an operation is not the first step

"The tumour is blocking my bowel. Does that mean emergency surgery and a stoma?"

Not necessarily. Where an obstructing tumour is found, a self-expanding metal stent can be placed through the colonoscope to reopen the passage without an operation. That buys time for full staging, for the patient's condition to be optimised, and for a planned operation to be performed instead of an emergency one. Where the tumour is advanced but not obstructing, local treatment is the other route to a more favourable operation.

Obstruction relieved without surgeryTime for full stagingPlanned instead of emergency operationPreservation kept in view

Keeping the sphincter: three routes to the same goal

For a low rectal tumour, the fear patients express most often is not the cancer but the prospect of a permanent stoma or of surviving with impaired control. There are three distinct ways to make preservation more likely, used alone or in combination.

Technical precision at operation

Robotic dissection in the narrow pelvis allows the tumour to be removed with a margin while the sphincter and its nerve supply are left intact. Even for tumours close to the anal verge, an ultra-low resection with a hand-sewn or stapled anastomosis can preserve continuity in selected patients.

Shrinking the tumour before operating

Where the tumour is too close or too bulky for immediate preservation, superselective transarterial infusion through the inferior mesenteric, superior rectal or internal iliac branches delivers drug concentrations 50 to 100 times higher than intravenous chemotherapy directly into the tumour, and drug-eluting embolisation adds sustained local delivery. After one to three sessions many tumours shrink enough that a sphincter-preserving operation becomes possible where a permanent stoma had been proposed.

Bridging an emergency to a planned operation

A stent placed through the colonoscope relieves the obstruction, converting an emergency presentation into a staged one. This is what allows the full assessment — imaging, molecular testing, nutrition and fitness — to be completed before the operation rather than after it.

What this does not promise. Some tumours genuinely require an abdominoperineal excision with a permanent stoma, and no technique changes that. Where a temporary stoma is used to protect a low anastomosis, it is usually reversed after healing — a different proposition from a permanent one. The plan should state which is being proposed and on what evidence.

Liver metastases: treated as a curable problem when they can be

Up to half of patients with colorectal cancer develop liver metastases, and this is the single most consequential fact in the disease — because colorectal liver deposits are among the most treatable metastases in oncology, provided the distribution allows them all to be dealt with.

Ablation for a few small deposits

For one to three small lesions, radiofrequency, microwave or cryoablation destroys the deposit through a needle under image guidance, with millimetre accuracy and without removing healthy liver. Combined with systemic therapy, this can bring patients to a state of no evidence of disease.

Arterial therapy for multiple or larger deposits

TACE, drug-eluting TACE and hepatic arterial infusion chemotherapy deliver treatment directly into the artery feeding the deposits, achieving local concentrations 50 to 100 times intravenous levels while sparing the rest of the liver. At our Guangzhou hospital the interventional team has performed more than 17,000 TACE procedures between 2023 and 2025.

Radiosurgery for deposits that cannot be operated on

Lesions sitting against a major vessel or in a deep segment are difficult to reach surgically and risky to ablate. CyberKnife converges radiation from thousands of angles at 0.1 mm precision, treating them while preserving the surrounding liver function.

These approaches are combined rather than chosen between: systemic therapy to control the disease systemically, and local treatment to clear what can be cleared. Whether an operation to remove all visible disease is realistic is the question the multidisciplinary meeting answers, and it is worth asking directly.

Radiotherapy, and radiosurgery for recurrence

Radiotherapy has two distinct roles in colorectal cancer: as part of the curative treatment of rectal cancer, where it reduces the risk of local recurrence in the pelvis and is often given before surgery to shrink the tumour, and as a local treatment for recurrences that cannot be operated on. Standard courses run over several weeks; shorter schedules are used in defined situations.

When the cancer returns in one place: radiosurgery instead of re-operation

"There is a new spot at the join, in a pelvic node, or in my lung. Do I need another major operation?"

Often not. CyberKnife M6 stereotactic radiosurgery delivers 0.1 mm precision with real-time tracking, converging beams from thousands of angles onto the target. Postoperative pelvic or anastomotic recurrences, regional lymph node relapses and isolated bone or lung deposits can be ablated in one to five outpatient sessions — without an incision, without adhesions, and without interrupting the systemic treatment already underway. Repeat abdominal surgery carries real morbidity in a pelvis that has already been operated on, and many patients are not candidates for it; radiosurgery avoids that question entirely. Our hospitals have performed more than 1,000 CyberKnife treatments.

No incisionNo adhesions1–5 outpatient sessionsSystemic treatment uninterrupted

Drug treatment: sequenced by molecular profile

Metastatic colorectal cancer requires successive lines of treatment, and which line works depends on what the tumour carries. The table below matches drug groups to molecular findings rather than to the order in which they are conventionally listed.

Molecular finding Drug groups used
MSI-H or mismatch repair deficient PD-1 immunotherapy, approved as first-line standard of care in China rather than reserved for later lines
RAS wild-type, left-sided tumour Anti-EGFR monoclonal antibodies combined with chemotherapy, sequenced appropriately
BRAF V600E Combined BRAF and EGFR inhibition, which outperforms standard chemotherapy in this group
HER2 amplified Anti-HER2 antibody combinations, including antibody-drug conjugates in previously treated disease
KRAS G12C Specific KRAS G12C inhibitors, already approved in China
After standard lines are exhausted Anti-angiogenic agents combined with immunotherapy, and phase III clinical trials of agents typically three to five years ahead of availability elsewhere
On cost, stated plainly. Because these agents are developed and manufactured within China's pharmaceutical ecosystem, the comprehensive cost of a course of treatment is typically 30%–50% of what the same course would cost in Europe or the United States. Metastatic colorectal cancer is treated over multiple lines, so this difference accumulates — and it often decides how many lines a patient can actually receive.

Finishing the course: managing what interrupts treatment

Colorectal cancer treatment extends over months, and the commonest reason a patient cannot complete it is the accumulation of side effects rather than the disease itself. Two are specific to this cancer.

Neuropathy and bowel dysfunction

Oxaliplatin causes a cold-sensitive neuropathy that can become persistent and is a frequent reason for stopping or reducing treatment. Postoperative bowel dysfunction — frequency, urgency and irregularity after a low resection — affects quality of life for months and is sometimes assumed to be untreatable. Integrative protocols combining herbal formulations and acupuncture are directed at both, alongside physical measures and dietary adjustment.

Stoma adaptation and recovery

Where a stoma is needed, whether temporary or permanent, specialist stoma care is part of the plan rather than a separate concern: appliance selection, skin management, and practical training before discharge. Patients who are prepared for a stoma manage it far better than those who are handed one on the ward, and this is a service we treat as part of the operation.

Integrative treatment is given as support alongside standard oncology treatment, supervised by clinicians who know what the patient is receiving.

A single recommendation, delivered in 48 hours

Why colorectal cancer is decided in a meeting

Colorectal cancer decisions cross departmental boundaries more than most: whether the sphincter can be preserved is a surgical and radiological question, whether liver deposits can be cleared is a hepatobiliary and interventional one, and which drug comes first is a molecular one. Colorectal surgery, hepatobiliary surgery, interventional radiology, medical oncology, radiation oncology, radiology and pathology review each case together and issue one written plan. Send your records and receive that plan within 48 hours of the file being complete — whether you intend to travel or want a second opinion to use at home.

If you are establishing what you have rather than what to do about it, begin with how colorectal cancer is diagnosed. The risk factors behind the disease and how they can be modified are covered in causes and risk factors and prevention and screening.

Frequently Asked Questions

Will I need a permanent stoma?

Not necessarily, and it is worth asking directly rather than assuming. Three approaches make preservation more likely: precise robotic dissection that preserves the sphincter and its nerve supply even for low tumours; interventional treatment, including superselective arterial infusion at concentrations 50 to 100 times those of intravenous chemotherapy, to shrink a bulky tumour until a preserving operation becomes possible; and a stent to relieve an obstruction so that a planned operation replaces an emergency one. Some tumours still genuinely require removal of the anal sphincter, and an honest plan will say so when that is the case. A temporary stoma used to protect a low join is different from a permanent one.

My cancer has spread to the liver. Is that the end of the road?

No — colorectal liver metastases are among the most treatable metastases in oncology, provided the distribution allows them all to be dealt with. For one to three small deposits, ablation destroys them through a needle; for multiple or larger deposits, treatment delivered into the hepatic artery reaches concentrations 50 to 100 times intravenous levels; and deposits in difficult positions can be treated with precision radiosurgery. Where all visible disease can be cleared, patients can reach a state of no evidence of disease, and a proportion remain there. Where it cannot, sustained control over years is a realistic aim with current drugs.

Why does the molecular test matter before choosing chemotherapy?

Because it changes which drug is worth giving. An MSI-high or mismatch repair deficient tumour should receive immunotherapy first — in China this is approved first-line treatment, not a later option — and giving chemotherapy instead would be a worse plan. A RAS mutation means anti-EGFR antibodies will not work, so giving them causes side effects without benefit. A BRAF V600E mutation calls for a specific combination. Testing after the first regimen has been chosen removes the chance to act on these findings.

Is it worth having treatment abroad rather than at home?

The honest criteria are access and cost rather than quality. If the drugs and the operation you need are available and affordable where you live, having treatment at home is usually better. Patients travel here for a gap in one of those two things: an agent not yet approved at home, a surgical technique for sphincter preservation that is not offered locally, an assessment for liver-directed treatment that requires a hepatobiliary and interventional team, or a cost that makes multiple lines of treatment unsustainable. Where that gap does not exist, our team will say so plainly.

Let our colorectal panel review your plan

Send your colonoscopy report, pathology, staging scans and molecular results, together with the treatment already proposed. Our multidisciplinary team will return a written assessment within 48 hours of the file being complete — including whether sphincter preservation is realistic and whether liver-directed treatment has a role.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*